Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SANT and BTB domain regulator of class switch recombination (SANBR) is a protein-coding gene encoding a protein that contains both a SANT and a BTB domain[3][4]. SANBR acts as a negative regulator of class switch recombination (CSR), a critical process in B cells by which immunoglobulin production shifts from IgM/IgD to other antibody isotypes in response to antigenic stimulation[1][5]. Overexpression of SANBR in mouse splenic B cells inhibits CSR, and this negative regulatory activity depends on the BTB domain, which mediates homodimerization and interactions with corepressor proteins such as HDAC and SMRT[1][2]. SANBR belongs to the KIAA1841 family of BTB domain-containing proteins and is predicted to function primarily as a DNA-binding protein involved in gene regulation relevant to antibody diversification[1][4][6]. No known therapeutics, small molecules, or biomarkers targeting SANBR have been described, and there are no reported safety concerns or clinically relevant drug interactions for this gene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SANT and BTB domain regulator of class switch recombination (SANBR).